Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/s41598-020-74988-9
- Scopus: eid_2-s2.0-85095938028
- PMID: 33188232
- WOS: WOS:000594638400003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis
Title | Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis |
---|---|
Authors | |
Issue Date | 2020 |
Publisher | Nature Research: Fully open access journals. The Journal's web site is located at http://www.nature.com/srep/index.html |
Citation | Scientific Reports, 2020, v. 10, p. article no. 19765 How to Cite? |
Abstract | This systematic review and meta-analysis investigated the comorbidities, symptoms, clinical characteristics and treatment of COVID-19 patients. Epidemiological studies published in 2020 (from January–March) on the clinical presentation, laboratory findings and treatments of COVID-19 patients were identified from PubMed/MEDLINE and Embase databases. Studies published in English by 27th March, 2020 with original data were included. Primary outcomes included comorbidities of COVID-19 patients, their symptoms presented on hospital admission, laboratory results, radiological outcomes, and pharmacological and in-patient treatments. 76 studies were included in this meta-analysis, accounting for a total of 11,028 COVID-19 patients in multiple countries. A random-effects model was used to aggregate estimates across eligible studies and produce meta-analytic estimates. The most common comorbidities were hypertension (18.1%, 95% CI 15.4–20.8%). The most frequently identified symptoms were fever (72.4%, 95% CI 67.2–77.7%) and cough (55.5%, 95% CI 50.7–60.3%). For pharmacological treatment, 63.9% (95% CI 52.5–75.3%), 62.4% (95% CI 47.9–76.8%) and 29.7% (95% CI 21.8–37.6%) of patients were given antibiotics, antiviral, and corticosteroid, respectively. Notably, 62.6% (95% CI 39.9–85.4%) and 20.2% (95% CI 14.6–25.9%) of in-patients received oxygen therapy and non-invasive mechanical ventilation, respectively. This meta-analysis informed healthcare providers about the timely status of characteristics and treatments of COVID-19 patients across different countries. |
Persistent Identifier | http://hdl.handle.net/10722/293390 |
ISSN | 2023 Impact Factor: 3.8 2023 SCImago Journal Rankings: 0.900 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, CKH | - |
dc.contributor.author | Wong, JYH | - |
dc.contributor.author | Tang, EHM | - |
dc.contributor.author | Au, CH | - |
dc.contributor.author | Wai, AKC | - |
dc.date.accessioned | 2020-11-23T08:16:03Z | - |
dc.date.available | 2020-11-23T08:16:03Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Scientific Reports, 2020, v. 10, p. article no. 19765 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | http://hdl.handle.net/10722/293390 | - |
dc.description.abstract | This systematic review and meta-analysis investigated the comorbidities, symptoms, clinical characteristics and treatment of COVID-19 patients. Epidemiological studies published in 2020 (from January–March) on the clinical presentation, laboratory findings and treatments of COVID-19 patients were identified from PubMed/MEDLINE and Embase databases. Studies published in English by 27th March, 2020 with original data were included. Primary outcomes included comorbidities of COVID-19 patients, their symptoms presented on hospital admission, laboratory results, radiological outcomes, and pharmacological and in-patient treatments. 76 studies were included in this meta-analysis, accounting for a total of 11,028 COVID-19 patients in multiple countries. A random-effects model was used to aggregate estimates across eligible studies and produce meta-analytic estimates. The most common comorbidities were hypertension (18.1%, 95% CI 15.4–20.8%). The most frequently identified symptoms were fever (72.4%, 95% CI 67.2–77.7%) and cough (55.5%, 95% CI 50.7–60.3%). For pharmacological treatment, 63.9% (95% CI 52.5–75.3%), 62.4% (95% CI 47.9–76.8%) and 29.7% (95% CI 21.8–37.6%) of patients were given antibiotics, antiviral, and corticosteroid, respectively. Notably, 62.6% (95% CI 39.9–85.4%) and 20.2% (95% CI 14.6–25.9%) of in-patients received oxygen therapy and non-invasive mechanical ventilation, respectively. This meta-analysis informed healthcare providers about the timely status of characteristics and treatments of COVID-19 patients across different countries. | - |
dc.language | eng | - |
dc.publisher | Nature Research: Fully open access journals. The Journal's web site is located at http://www.nature.com/srep/index.html | - |
dc.relation.ispartof | Scientific Reports | - |
dc.rights | Scientific Reports. Copyright © Nature Research: Fully open access journals. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis | - |
dc.type | Article | - |
dc.identifier.email | Wong, CKH: carlosho@hku.hk | - |
dc.identifier.email | Wong, JYH: janetyh@hku.hk | - |
dc.identifier.email | Tang, EHM: erichm@hku.hk | - |
dc.identifier.email | Au, CH: auchiho@hku.hk | - |
dc.identifier.email | Wai, AKC: awai@hku.hk | - |
dc.identifier.authority | Wong, CKH=rp01931 | - |
dc.identifier.authority | Wong, JYH=rp01561 | - |
dc.identifier.authority | Wai, AKC=rp02261 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1038/s41598-020-74988-9 | - |
dc.identifier.pmid | 33188232 | - |
dc.identifier.pmcid | PMC7666204 | - |
dc.identifier.scopus | eid_2-s2.0-85095938028 | - |
dc.identifier.hkuros | 319631 | - |
dc.identifier.volume | 10 | - |
dc.identifier.spage | article no. 19765 | - |
dc.identifier.epage | article no. 19765 | - |
dc.identifier.isi | WOS:000594638400003 | - |
dc.publisher.place | United Kingdom | - |